|
Dr. David C. U'Prichard currently serves as a President of Druid Consulting LLC, consulting to the pharmaceutical and biotechnology industries and as a Venture Partner at Red Abbey Venture Partners (Baltimore) and Care Capital LLC (Princeton). From 1997 to 1999, Dr. U'Prichard served as Chairman of Research and Development at SmithKline Beecham. Prior to SmithKline Beecham, he worked for ICI/Zeneca as Executive Vice President and International Research Director. Dr. U'Prichard was instrumental in the launch of Nova Pharmaceuticals, Baltimore MD in 1983, following an academic career as Associate Professor of Pharmacology and Neurobiology at Northwestern University Medical School. Dr. U'Prichard received his Ph.D. in Pharmacology from the University of Kansas, and his B.S. in Pharmacology with first-class honors from the University of Glasgow, Scotland. He has held academic appointments at Northwestern University, Johns Hopkins University and the University of Pennsylvania and is an Honorary Professor at the University of Glasgow. He has authored more than 100 primary and review publications, was a founding co-editor of Molecular Neurobiology and co-editor of Epinephrine in the Central Nervous System. Dr. U'Prichard is Chairman of the Board of Cyclacel Pharmaceuticals Inc. and Oxagen Ltd and serves on the Board of Directors of Invitrogen Corp, SMART Biosciences, Inc. and SR Pharma PLC. Dr. U'Prichard was Chairman of the Pennsylvania Biotechnology Association from 2004-2005. Dr. U'Prichard is a consultant for Booz Allen Hamilton, is a Trustee of the International House of Philadelphia and is on the Board of the Bioethics Institute of the University of Pennsylvania. | 